Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.

Account Information Already have an account? Log in here

LEAVE THIS BLANK

Welcome Email

By selecting this, I agree to receive emails from fenix.group.

You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.
RETURN TO HOME
$599
Dual/triple agonist, GLP-1RA, Other, Topics

Obesity Spotlight Series: Emerging Players to Watch

Here is a brief preview of this blast: In the thirteenth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a brief analysis of the emerging players in the obesity market. While previous editions of the spotlight series focused on the major players competing in the space, there is no shortage of smaller biotechs that could also shape the landscape in years to come. In this spotlight, FENIX highlights 10 smaller obesity players to watch (as well as honorable mentions), assessing their pipeline progress, competitive positioning, and potential attractiveness as future M&A targets.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.